Circulating irisin levels in newly diagnosed obstructive sleep apnea patients

Introduction: Obstructive sleep apnea syndrome (OSAS) is commonly associated with obesity, insulin resistance, metabolic syndrome, hypertension, and coronary artery disease. Irisin is a newly identified myokine and its serum concentration was found to be correlated with cardiac troponin and creatin kinase-MB in acute myocardial infarction patients. Furthermore, irisin levels were positively associated with endothelium-dependent vasodilation in type 2 diabetic patients.Aim: In this study, we aimed to investigate serum irisin level in the newly diagnosed OSAS patients.Materials and Methods: After obtaining ethical approval, 32 OSAS patients were included. All patients gave written informed consent. Diagnosis of OSAS was verified by an overnight polysomnography (PSG) and made by an apnea hypopnea index equal to or higher than 5. Venous blood samples were collected in the morning between 08.00 – 10.00 after PSG (n=25) or after one-night CPAP treatment (n=7). Serum irisin concentrations were studied by ELISA.Results and Conclusion: Serum irisin concentrations were significantly higher in newly diagnosed OSAS group than in OSAS group after one night of CPAP treatment (199.7±42.4 vs 159.7±18.3 ng/mL respectively; p<0.01). These results suggest that increased serum irisin levels can be reduced by CPAP treatment and elevated serum irisin levels may be due to increased respiratory muscle activity and body temperature.

Evaluation of ureteral jet dynamics in pediatric kidney stone formers: A cross-sectional study

Introductio

Calcitonin related polypeptide alpha gene polymorphisms according to plasma total homocysteine levels in ischemic stroke patients of Trakya Region

<p>The aim of this study was to determine the genotype distributions of calcitonin related polypeptide alpha (CALCA) gene polymorphisms according to the plasma total homocysteine levels in ischemic stroke patients and patient subtypes selected from Trakya Region. The study included 82 patients and 92 healthy controls. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) were used to determine the genotype distributions of CALCA gene polymorphisms. The plasma total homocysteine levels were measured by Immulite 2000XPi homocysteine kits. Significant differences were not found between the group of patients and the control group in terms of CALCA gene polymorphisms genotype distributions (<i>p</i> > 0.05). Significant differences were not found between ischemic stroke patients and healthy controls, in the patient subtypes with ischemic stroke in respect to the CALCA gene polymorphisms genotype distributions according to the plasma total homocysteine levels (<i>p</i> > 0.05). This suggests that the CALCA gene polymorphisms genotype distributions studied according to the plasma total homocysteine levels could not likely be considered a genetic risk factor for ischemic stroke development.</p

Assessment of the Relationship Between Vitamin D Level and Non-specific Musculoskeletal System Pain: A Multicenter Retrospective Study (Stroke Study Group)

Objective: In this study, it was aimed to evaluate the relationship between vitamin D level and pain severity, localization and duration in patients with non-specific musculoskeletal pain

Antifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey

WOS: 000452555000048PubMed ID: 30121343Objectives: The aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey. Methods: A point prevalence study was performed at 25 hospitals. In addition to general data on paediatric units of the institutes, the generic name and indication of antifungal drugs, the presence of fungal isolation and susceptibility patterns, and the presence of galactomannan test and high-resolution computed tomography (HRCT) results were reviewed. Results: A total of 3338 hospitalised patients were evaluated. The number of antifungal drugs prescribed was 314 in 301 patients (9.0%). Antifungal drugs were mostly prescribed in paediatric haematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%), paediatric services (18.3%), paediatric ICUs (PICUs) (14.6%) and haematopoietic stem cell transplantation (HSCT) units (7.3%). Antifungals were used for prophylaxis in 147 patients (48.8%) and for treatment in 154 patients (50.0%). The antifungal treatment strategy in 154 patients was empirical in 77 (50.0%), diagnostic-driven in 29 (18.8%) and targeted in 48 (31.2%). At the point of decision-making for diagnostic-driven antifungal therapy in 29 patients, HRCT had not been performed in 1 patient (3.4%) and galactomannan test results were not available in 12 patients (41.4%). Thirteen patients (8.4%) were receiving eight different antifungal combination therapies. Conclusion: The majority of antifungal drugs for treatment and prophylaxis were prescribed in PHO and HSCT units (42.5%), followed by ICUs. Thus, antifungal stewardship programmes should mainly focus on these patients within the availability of diagnostic tests of each hospital. (C) 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved

Antifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey

Objectives: The aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey